Previous 10 | Next 10 |
home / stock / nvs / nvs articles
Novartis AG (NYSE: NVS) announced topline results from the six-month, double-blind period of the Phase 3 APPEAR-C3G study of iptacop...
The FDA approved Novartis AG's (NYSE: NVS) Fabhalta (iptacopan) as the first oral monotherapy for adult patients with paroxysmal...
Tuesday, the FDA said it received reports of patients developing T-cell malignancies, including chimeric antigen receptor CAR-positive ly...
Novartis AG (NYSE: NVS) released topline results from the interim analysis of the ongoing pivotal Phase 3 ALIGN study of atrasentan in patient...
The third-quarter earnings season has largely been mixed so far, reflecting the impact of the economic uncertainties on profit growth. That said, d...
The U.S. Food and Drug Administration has recently issued a stern warning to the public, advising against the purchase and use of multipl...
Stocks enjoyed a positive midday trading session in New York, with all major indices in the green. Additionally, nine out of 11 S&P 500 sectors...
Buoyed by earnings optimism, stocks appear on track for a positive open on Tuesday after the tech-heavy Nasdaq Composite Index snapped a four-day l...
Novartis AG (NYSE: NVS) reported Q3 FY23 sales of $11.78 billion, up 12% Y/Y in reported and constant currency (cc), beating the con...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...